SCHEDULE: FMR LLC Reduces Taysha Gene Therapies Stake Below 5%

Sentiment:

Beneficial Ownership Amendment 5 February 2026 1:40 PM

📋All filings for Taysha Gene Therapies, INC

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 4.9% in Taysha Gene Therapies Inc., marking a reduction below the 5% threshold.

Worse than expectedFMR LLC and Abigail P. Johnson's beneficial ownership in Taysha Gene Therapies Inc. has decreased to 4.9% of the common stock.This reduction means their stake is now below the 5% threshold, which often triggers a re-evaluation by other investors and can be perceived negatively.

Summary

FMR LLC and Abigail P. Johnson collectively beneficially own 13,528,365.87 shares of Taysha Gene Therapies Inc. common stock.
This ownership represents 4.9% of the company's total outstanding common stock.
FMR LLC holds sole voting power over 13,519,174.00 shares and sole dispositive power over 13,528,365.87 shares.
Abigail P. Johnson, as a control person of FMR LLC, is also deemed to beneficially own the same shares with sole dispositive power.
This filing is Amendment No. 10, indicating a change from previous disclosures, specifically a reduction in beneficial ownership to below the 5% threshold.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal, as a significant institutional investor has reduced its stake below a key reporting threshold, potentially indicating a shift in investment strategy or outlook for Taysha Gene Therapies.

Negatives

FMR LLC and Abigail P. Johnson have reduced their beneficial ownership in Taysha Gene Therapies Inc. to 4.9%, falling below the 5% reporting threshold.
This reduction by a significant institutional investor could be interpreted by the market as a decrease in confidence or a strategic reallocation of capital.

Future Outlook

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially from major asset managers like FMR LLC (Fidelity), are closely watched in the biotechnology and gene therapy sector. A reduction in stake by a prominent investor can sometimes signal a re-evaluation of the company's prospects or a reallocation of capital within the sector.

Comparison to Industry Standards

StockSavvy.ai observes that Schedule 13G filings are standard regulatory disclosures for institutional investors holding between 5% and 20% of a company's stock, or for those who previously held above 5% and have now fallen below. The filing adheres to SEC requirements for reporting beneficial ownership changes.
No specific comparable companies, projects, or results are relevant for this type of compliance filing, as it pertains to a regulatory disclosure of ownership rather than operational performance.

Stakeholder Impact

Shareholders: May interpret the reduction in FMR LLC's stake as a negative signal, potentially leading to downward pressure on the stock price.
Company Management: Could face increased scrutiny regarding investor confidence and strategic direction following the reduction in a major institutional holding.

Key Dates

Date	Description
2023-01-03	Effective date of Power of Attorney for FMR LLC.
2023-01-10	Date of Schedule 13G filing by FMR LLC (accession number -23-000003) where Power of Attorney is incorporated by reference.
2023-01-26	Effective date of Power of Attorney for Abigail P. Johnson.
2023-01-31	Date of Schedule 13G filing by FMR LLC (accession number -23-000038) where Abigail P. Johnson's Power of Attorney is incorporated by reference.
2025-12-31	Date of event which requires filing of this statement (reporting period end).
2026-02-04	Signature date of the Schedule 13G filing.

Recommendation

sell

The reduction of a significant institutional investor's stake, particularly FMR LLC, to below the 5% threshold is a bearish signal. It suggests that a major player has reduced its exposure, potentially due to concerns about the company's future prospects or a re-evaluation of its investment thesis. This could lead to further selling pressure and a decline in investor confidence, warranting a 'sell' recommendation for investors seeking to mitigate risk.

Keywords

Taysha Gene Therapies, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Ownership, Gene Therapy, Biotechnology, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.